What Is Bacitracin Used For? Approved Uses, Per the Label
Bacitracin is an approved antibacterial medicine in the United States, available as a prescription ophthalmic ointment and as an over the counter first aid ointment under the FDA monograph system. Labeling for the ophthalmic product covers superficial ocular infections of the conjunctiva and cornea caused by susceptible organisms, and the first aid product covers prevention of infection in minor cuts, scrapes and burns. An injectable form was once labeled for infant staphylococcal pneumonia and empyema and was later withdrawn. Personal use questions belong with a prescribing clinician.
Bacitracin at a Glance
Bacitracin is an approved antibacterial medicine in the United States. It is marketed in two regulated forms: a prescription ophthalmic ointment, and an over the counter first aid antibiotic ointment sold under the US over the counter monograph system for topical antibiotics. Chemically it is a cyclic peptide produced by Bacillus bacteria, and it belongs to the nonribosomal peptide family, a class whose assembly line chemistry was described in detail in a 2025 structural study of condensation domains in nonribosomal peptide synthesis (PMID 39662504).
This page summarises only what approved US labeling covers, plus the regulatory history of those indications and the published literature available in the verified source set. It does not provide dosing, administration instructions or personal recommendations. This page is for educational purposes only and is not medical advice; consult a licensed physician or another qualified prescribing clinician about any question involving a specific person.
Approved Uses, As Worded on US Labeling
Prescription ophthalmic ointment
US labeling for bacitracin ophthalmic ointment describes the product as indicated for the treatment of superficial ocular infections involving the conjunctiva and/or the cornea that are caused by organisms susceptible to bacitracin. That indication is organism dependent rather than symptom dependent: the labeled wording ties use to susceptibility, which is why microbiology, and not appearance alone, drives the decision made by a prescribing clinician. The sources cited on this page do not supply a specific label revision year for any individual manufacturer's ophthalmic product, so no revision date is asserted here.
Over the counter first aid ointment
Topical bacitracin ointment marketed under the over the counter monograph carries first aid wording: it is labeled to help prevent infection in minor cuts, scrapes and burns. The monograph framing is preventive and limited to minor skin injuries. Deeper wounds, puncture wounds, animal bites and serious burns fall outside that labeled wording, which is why the labeling directs consumers toward a health professional in those situations. Again, no revision year is claimed here because the verified sources used for this page do not supply one.
Injectable bacitracin, a historical indication
Bacitracin for injection was previously approved in the United States with an intramuscular indication for the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. That indication was narrow by design and reflected an era of paediatric staphylococcal disease management that predates most current antistaphylococcal options. The injectable product was subsequently removed from the US market after the FDA requested voluntary withdrawal, and systemic bacitracin is therefore no longer an available labeled option in the United States.
Summary table of labeled indications
| Product form | Regulatory pathway | Indication as carried on US labeling | Current status |
|---|---|---|---|
| Ophthalmic ointment | Prescription | Treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by susceptible organisms | Marketed |
| Topical first aid ointment | Over the counter monograph | First aid to help prevent infection in minor cuts, scrapes and burns | Marketed |
| Bacitracin for injection | Prescription | Treatment of infants with pneumonia and empyema caused by susceptible staphylococci | Withdrawn from the US market |
Pivotal Trials Behind the Indications
Bacitracin entered clinical use long before randomised registration trials became the standard basis for US marketing authorisation, and the verified source set assembled for this page contains no pivotal registration trial for any bacitracin indication. Where no pivotal trial record is available in the cited literature, none is invented here. The practical consequence is that the approved wording rests on an older evidentiary record, with modern published work consisting largely of microbiology surveys, in vitro comparisons and susceptibility studies rather than controlled efficacy trials.
Several of those modern studies describe the bacterial landscape that the labeled indications address. Researchers examining postcataract endophthalmitis reported changing trends in the organisms recovered from affected eyes and in their antibiotic susceptibility patterns across the study period (PMID 15767476). The study illustrates why ocular labeling is written around susceptible organisms rather than around a fixed list of diagnoses.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeRegulatory History of the Indications
Three regulatory threads are worth separating. First, the ophthalmic prescription indication has remained the principal prescription use of bacitracin in the United States, and its wording has stayed organism linked. Second, the topical first aid wording sits in a different regulatory system entirely: over the counter monograph products are marketed without an individual product approval when they conform to the monograph's established conditions for active ingredient, labeling and intended use. Third, the injectable indication was withdrawn from the US market following an FDA request for voluntary withdrawal, which ended systemic bacitracin availability in the country.
Because these three threads have separate histories, statements such as "bacitracin is approved" are only meaningful when attached to a formulation. An approved ophthalmic indication says nothing about systemic use, and a monograph first aid claim says nothing about treating an established infection.
What the Published Literature Reports
Topical antimicrobials and burn wound isolates
A 2020 in vitro study evaluated the efficacy of topical antimicrobial agents against bacterial isolates recovered from burn wounds, and researchers reported differences between agents in activity against those isolates (PMID 32303755). The study measured laboratory activity against clinical isolates rather than healing outcomes in patients, so it describes microbiological behaviour and not a labeled claim.
Surgical irrigation and biofilm formation
An in vitro study of surgical irrigation solutions reported on their performance in preventing biofilm formation on implant materials (PMID 41270988). Work of this kind sits in the surgical and laboratory literature and does not correspond to any bacitracin indication carried on US labeling.
Bacitracin in laboratory microbiology media
Bacitracin also appears in diagnostic microbiology as a selective agent. Researchers comparing three selective media for the isolation of Aggregatibacter actinomycetemcomitans reported differences between the media in recovery of the target organism (PMID 23278666). This is a laboratory application of the molecule rather than a therapeutic indication.
Wider antibacterial research context
Separate strands of antibacterial research examine adjuvants and repurposed molecules rather than bacitracin itself. One study reported that the menaquinone pathway was important for susceptibility of Staphylococcus aureus to the antibiotic adjuvant cannabidiol (PMID 35091344), and another reported that zinc activated avobenzone inhibited methicillin resistant Staphylococcus aureus in laboratory testing (PMID 37653446). Neither line of work establishes an indication for any marketed product.
Tracking research? Log entries with dates, lots and notes: records, never plans.
Get the appUses That Are Not Approved
One short factual note belongs here. Published work has explored decolonisation of resistant organisms and intracavitary antibiotic instillation, for example a 2018 study of ebselen repurposed for decolonisation of vancomycin resistant enterococci (PMID 29953486) and a comparative study of prophylactic intracavitary antibiotic instillation into the pneumonectomy space (PMID 11343560). Decolonisation regimens, surgical irrigation protocols and cavity instillation are not approved bacitracin indications in the United States, and they are described here only as published research, not as uses.
Tolerability and Adverse Events: What Studies Report
The verified source set assembled for this page does not contain clinical safety trials of bacitracin, so no adverse event rates, frequencies or severity grades are quoted. The cited studies reported laboratory endpoints rather than patient outcomes: researchers measured in vitro activity of topical antimicrobial agents against bacterial isolates from burn wounds (PMID 32303755), and a separate in vitro study reported biofilm formation on implant surfaces after exposure to surgical irrigation solutions (PMID 41270988).
Microbiology surveys in the same source set likewise reported organism level observations rather than tolerability data; one survey reported changing patterns among isolates recovered in postcataract endophthalmitis (PMID 15767476), and a media comparison reported recovery differences for a periodontal pathogen (PMID 23278666). Safety questions, including questions about hypersensitivity or local reactions, belong with a prescribing clinician who can review the current product information for the specific product in question.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeQuestions a Prescribing Clinician Can Answer
- Which bacitracin containing product, if any, matches the clinical situation being discussed.
- Whether the organism involved falls within the susceptibility based wording of the ophthalmic indication.
- Whether an injury is minor enough to fall within the first aid monograph wording.
- How allergy history and prior reactions to topical antibiotics affect the decision.
- What alternatives exist now that systemic bacitracin is no longer marketed in the United States.
Related Reading
For background on bacitracin's chemistry, mechanism and research literature, see the bacitracin overview.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeReferences
- Structures and mechanism of condensation in non-ribosomal peptide synthesis (Nature, 2025)
- Changing trends in the microbiologic aspects of postcataract endophthalmitis (Archives of Ophthalmology, 2005)
- Efficacy of Topical Antimicrobial Agents Against Bacterial Isolates From Burn Wounds (Journal of Burn Care & Research, 2020)
- The In Vitro Performance of Surgical Irrigation Solutions in Preventing Biofilm Formation on Implants (The Journal of Arthroplasty, 2026)
- Evaluation of three selective media for isolation of Aggregatibacter actinomycetemcomitans (Journal of Periodontal Research, 2013)
- The menaquinone pathway is important for susceptibility of Staphylococcus aureus to the antibiotic adjuvant, cannabidiol (Microbiological Research, 2022)
- Repurposing sunscreen as an antibiotic: zinc-activated avobenzone inhibits methicillin-resistant Staphylococcus aureus (Metallomics, 2023)
- Repurposing ebselen for decolonization of vancomycin-resistant enterococci (VRE) (PLoS One, 2018)
- Prophylactic intracavitary (pneumonectomy space) antibiotic instillation: a comparative study (Annals of Thoracic and Cardiovascular Surgery, 2001)
Frequently asked questions
What is bacitracin used for according to US labeling?▾
Labeling for the prescription ophthalmic ointment covers treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by susceptible organisms. The over the counter first aid ointment is labeled to help prevent infection in minor cuts, scrapes and burns. An injectable product was previously labeled for infants with staphylococcal pneumonia and empyema. Whether any product fits a given situation is a prescribing clinician's decision.
What is the regulatory status of bacitracin in the United States?▾
Bacitracin is an approved antibacterial medicine. The ophthalmic ointment is a prescription product, while topical first aid ointment is marketed under the over the counter monograph system for topical antibiotics. The injectable formulation was withdrawn from the US market after the FDA requested voluntary withdrawal, so systemic bacitracin is no longer marketed domestically.
Which pivotal trials support the approved indications?▾
The verified source set for this page contains no pivotal registration trial for any bacitracin indication, and bacitracin's clinical introduction predates modern controlled trial based registration. Available modern literature consists mainly of microbiology surveys and in vitro comparisons, such as a survey of organisms recovered in postcataract endophthalmitis (PMID 15767476) and in vitro testing of topical antimicrobials against burn wound isolates (PMID 32303755).
Do laboratory studies of bacitracin create additional approved uses?▾
No. Laboratory findings are not indications. Researchers have used bacitracin containing selective media to isolate periodontal pathogens (PMID 23278666), and separate in vitro work has compared surgical irrigation solutions for prevention of implant biofilm formation (PMID 41270988). These are research and diagnostic applications that sit outside the wording carried on US product labeling.
What do studies report about uses outside the label?▾
Published research has examined decolonisation of vancomycin resistant enterococci using repurposed agents (PMID 29953486) and prophylactic intracavitary antibiotic instillation after pneumonectomy (PMID 11343560). Those settings are not approved bacitracin indications in the United States. They are described in the literature as investigational or procedural research, and any clinical question about them belongs with a prescribing clinician.
What do the cited studies report about safety?▾
The verified source set contains no clinical safety trials of bacitracin, so no adverse event rates are quoted on this page. The cited studies reported laboratory endpoints instead, including in vitro activity against burn wound isolates (PMID 32303755) and biofilm formation on implant surfaces exposed to irrigation solutions (PMID 41270988). Safety questions should be directed to a prescribing clinician reviewing the current product information.
Why is the ophthalmic indication written around susceptible organisms?▾
The labeled wording ties treatment to organisms susceptible to bacitracin rather than to a diagnosis alone, because susceptibility patterns shift over time. Researchers reporting on postcataract endophthalmitis described changing trends in the organisms recovered and their susceptibility profiles (PMID 15767476), which is why microbiological context matters to the clinician applying the indication.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.